A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

NCT05584332 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

3131

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic adjustment

Conditions

Cervical Cancer
Genital Wart
CIN1
CIN2
CIN3
Vain I
Vain III
Vin I
Vin II
Vin III
AIS
VAIN - Vaginal Intraepithelial Neoplasia 2

Interventions

BIOLOGICAL: Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
BIOLOGICAL: Placebo

Sponsor

Shanghai Bovax Biotechnology Co., Ltd.